Wall Street Zen Upgrades Inhibikase Therapeutics (NASDAQ:IKT) to “Sell”

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Inhibikase Therapeutics in a research note on Thursday. Finally, Chardan Capital restated a “neutral” rating and issued a $1.50 target price on shares of Inhibikase Therapeutics in a report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $4.75.

Read Our Latest Report on IKT

Inhibikase Therapeutics Price Performance

NASDAQ IKT opened at $1.52 on Friday. Inhibikase Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $2.61. The stock has a market cap of $213.21 million, a price-to-earnings ratio of -3.80 and a beta of 0.94. The business has a fifty day moving average of $1.90 and a 200-day moving average of $1.93.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. As a group, analysts anticipate that Inhibikase Therapeutics will post -0.41 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IKT. Kalehua Capital Management LLC grew its position in Inhibikase Therapeutics by 118.4% during the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock valued at $6,421,000 after acquiring an additional 2,071,890 shares during the period. SummitTX Capital L.P. purchased a new position in shares of Inhibikase Therapeutics in the 1st quarter worth about $2,561,000. Ally Bridge Group NY LLC purchased a new position in shares of Inhibikase Therapeutics in the 1st quarter worth about $2,226,000. Seven Fleet Capital Management LP raised its holdings in shares of Inhibikase Therapeutics by 6.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company’s stock worth $704,000 after purchasing an additional 21,300 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Inhibikase Therapeutics by 595.3% in the 1st quarter. Bank of America Corp DE now owns 322,704 shares of the company’s stock valued at $542,000 after purchasing an additional 276,293 shares in the last quarter. Institutional investors and hedge funds own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

(Get Free Report)

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

See Also

Analyst Recommendations for Inhibikase Therapeutics (NASDAQ:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.